Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
6.15 6.05 6.04 6.05 6.08 Last
22204010 34321480 38024970 33386540 45798210 Volume
0.00% -1.63% -0.17% +0.17% +0.50% Change
Estimated financial data (e)
Sales 2021 34 800 M 4 469 M 4 469 M
Net income 2021 12 579 M 1 615 M 1 615 M
Net cash position 2021 11 849 M 1 522 M 1 522 M
P/E ratio 2021 9,58x
Yield 2021 2,28%
Sales 2022 41 091 M 5 277 M 5 277 M
Net income 2022 7 892 M 1 013 M 1 013 M
Net cash position 2022 15 134 M 1 943 M 1 943 M
P/E ratio 2022 15,1x
Yield 2022 1,55%
Capitalization 114 B 14 646 M 14 644 M
EV / Sales 2021 2,94x
EV / Sales 2022 2,41x
Nbr of Employees 24 443
Free-Float 52,2%
More Financials
Company
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%). 
Sector
Pharmaceuticals
Calendar
03/31Earnings Release
More about the company
Ratings of Sino Biopharmaceutical Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SINO BIOPHARMACEUTICAL LIMITED
12:39aSino Biopharm's Anti-Rheumatic Drug Wins Marketing Approval in China
MT
01/20Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection..
CI
01/11Chinese Regulators OK Sino Biopharma's Generic Diabetes Treatment for Marketing in Chin..
MT
01/10Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate and Metformin Hydrochlor..
CI
01/03Hong Kong Hang Seng Sheds 0.5% as Property Issues Renew Slump
MT
2021Sino Biopharmaceutical Buys Back 4.5 Million More Shares
MT
2021Sino Biopharm Wins Nod to Start China Clinical Trial of Cough Medicine
MT
2021Sino Biopharmaceutical to Become Sole Sales Agent of Hodgkin's Lymphoma Treatment Produ..
MT
2021Sino Biopharmaceutical Limited's TCR1672 Obtains Approval for Clinical Trial
CI
2021Sino Biopharmaceutical Limited Enters into an Exclusive Sales Agreement with CTTQ-Akeso..
CI
2021Hong Kong Hang Seng Up 0.2% As Property, Tech Sectors Lift
MT
2021Hong Kong Hang Seng Down 0.9% on New US Sanctions Reports
MT
2021Sino Biopharmaceutical Buys Back 9 Million More Shares
MT
2021Hong Kong Hang Seng Up 2.7%, Property and Tech Sectors Surge
MT
2021China’s $1.1 Trillion Healthcare Sector to Grow 9.5% Annually in 10 Years, Nomura..
MT
More news
News in other languages on SINO BIOPHARMACEUTICAL LIMITED
12:39aLe médicament antirhumatismal de Sino Biopharm obtient l'autorisation de mise sur le ma..
01/20Sino Biopharmaceutical Limited annonce l'approbation de la commercialisation de la "sol..
01/11Les autorités réglementaires chinoises autorisent la commercialisation en Chine du trai..
01/10Sino Biopharmaceutical Limited annonce que les comprimés de phosphate de sitagliptine e..
01/03Le Hang Seng de Hong Kong perd 0,5 % alors que les émissions immobilières reprennent le..
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | 1177 | KYG8167W1380 | MarketScreener
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 6,08 HKD
Average target price 10,53 HKD
Spread / Average Target 73,1%
EPS Revisions
Managers and Directors
Yi Li Chief Executive Officer & Executive Director
Theresa Tse Chairman
Hsuan Tse General Manager-Information Management
Wei Nong Ye General Manager-Research & Development
Mao Li Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED10.81%14 574
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833